Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(1.12) by 27.68 percent. This is a 49.38 percent increase over losses of $(1.60) per share from the same period last year. The company reported quarterly sales of $25.555 million which beat the analyst consensus estimate of $23.178 million by 10.26 percent. This is a 42.30 percent increase over sales of $17.958 million the same period last year.